Intrexon Corporation (XON) Expected to Post Quarterly Sales of $48.79 Million
Wall Street brokerages forecast that Intrexon Corporation (NYSE:XON) will post $48.79 million in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Intrexon’s earnings. The lowest sales estimate is $44.65 million and the highest is $51.91 million. Intrexon posted sales of $46.00 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 6.1%. The firm is scheduled to report its next quarterly earnings results on Wednesday, March 7th.
According to Zacks, analysts expect that Intrexon will report full-year sales of $48.79 million for the current year, with estimates ranging from $197.50 million to $206.11 million. For the next financial year, analysts forecast that the firm will post sales of $249.15 million per share, with estimates ranging from $217.00 million to $281.22 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that cover Intrexon.
A number of research firms have recently issued reports on XON. Northland Securities set a $30.00 price target on Intrexon and gave the company a “buy” rating in a research report on Monday, August 7th. BidaskClub lowered Intrexon from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. JMP Securities restated an “outperform” rating and issued a $42.00 price target on shares of Intrexon in a research report on Thursday, October 5th. Griffin Securities restated a “buy” rating and issued a $55.00 price target on shares of Intrexon in a research report on Friday, October 6th. Finally, Bank of America dropped their price target on Intrexon from $25.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, November 10th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the company’s stock. Intrexon presently has a consensus rating of “Hold” and an average target price of $38.50.
A number of institutional investors have recently modified their holdings of XON. Teachers Advisors LLC lifted its stake in Intrexon by 6.8% during the first quarter. Teachers Advisors LLC now owns 53,606 shares of the biotechnology company’s stock worth $1,062,000 after purchasing an additional 3,434 shares in the last quarter. Legal & General Group Plc lifted its stake in Intrexon by 102.5% during the first quarter. Legal & General Group Plc now owns 18,450 shares of the biotechnology company’s stock worth $365,000 after purchasing an additional 9,340 shares in the last quarter. Sei Investments Co. lifted its stake in Intrexon by 1.6% during the second quarter. Sei Investments Co. now owns 122,220 shares of the biotechnology company’s stock worth $2,944,000 after purchasing an additional 1,895 shares in the last quarter. Baxter Bros Inc. acquired a new position in Intrexon during the second quarter worth $231,000. Finally, National Planning Corp lifted its stake in Intrexon by 13.4% during the second quarter. National Planning Corp now owns 12,958 shares of the biotechnology company’s stock worth $316,000 after purchasing an additional 1,528 shares in the last quarter. Institutional investors own 77.39% of the company’s stock.
Shares of Intrexon (XON) opened at $13.55 on Friday. The company has a quick ratio of 1.85, a current ratio of 2.05 and a debt-to-equity ratio of 0.01. Intrexon has a 52 week low of $10.26 and a 52 week high of $30.96.
WARNING: “Intrexon Corporation (XON) Expected to Post Quarterly Sales of $48.79 Million” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/intrexon-corporation-xon-expected-to-post-quarterly-sales-of-48-79-million/1738593.html.
Intrexon Company Profile
Intrexon Corporation (Intrexon) forms collaborations to create biologically-based products and processes using synthetic biology. The Company’s domestic operations are in California, Florida, Maryland, and Virginia, and its primary international operations are in Belgium and Hungary. The Company designs, builds and regulates gene programs, which are deoxyribonucleic acid (DNA) sequences that consist of genetic components.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Intrexon Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.